Why the study?
SGLT2 inhibitors have been associated with lower rates of cardiac arrhythmias in post hoc analyses, but their real-world effect on cardiac arrhythmias remains incompletely defined.
Does sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy reduce the incidence of atrial arrhythmias in hospitalized patients with type 2 diabetes mellitus?
Does sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy reduce the incidence of atrial arrhythmias in hospitalized patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
In a real-world hospitalized cohort of patients with type 2 diabetes mellitus, SGLT2i therapy was associated with an 83% lower hazard of incident atrial arrhythmias at 2 years despite a higher unmeasured comorbidity burden in the treated group.
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been associated with lower rates of cardiac arrhythmias in post hoc analyses. The real-world effect on cardiac arrhythmias is incompletely defined. Objective The purpose of this study was to determine the effects of SGLT2i on cardiac arrhythmias in a real-world, hospitalized population. Methods A retrospective cohort study was performed in South Australia, Australia. Patients (n = 882) with type 2 diabetes mellitus (T2DM) on oral diabetic therapy (33.6% females, median age 62.3 years) who received SGLT2i (for T2DM) were identified through public hospital admissions from 2011–2019. Patients were matched with 3282 contemporaneous controls with T2DM who did not receive SGLT2i. Baseline characteristics were adjusted using inverse probability treatment weighting. The primary outcome was incidence of atrial arrhythmias. Secondary outcomes included incidence of ventricular arrhythmias and cardiac arrest at 2 years. Results All-cause mortality was higher in the SGLT2i group (hazard ratio [HR] 2.02, 95% confidence interval [CI] 1.55–2.63, P <.001) despite propensity matching, highlighting the greater unmeasured comorbidity burden of the SGLT2i-treated group. Despite this, SGLT2i treatment was associated with fewer atrial arrhythmias (HR 0.17, 95% CI 0.07–0.41, P <.001) at 2 years. The relationship between SGLT2i use and ventricular arrhythmias (HR 0.25, 95% CI 0.06–1.03, P = .055) and cardiac arrest (HR 0.82, 95% CI 0.20–3.45, P = .796) did not reach statistical significance. Conclusion In this real-world, comorbid inpatient cohort, SGLT2i treatment was associated with a lower incidence of atrial arrhythmias. Prospective randomized trials evaluating SGLT2i as specific atrial fibrillation pharmacotherapy are underway.
No takes yet. Share an insight, caveat, or question.
Tiver et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: